222 related articles for article (PubMed ID: 25773545)
1. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Guðbrandsdottir G; Hjelle KM; Frugård J; Bostad L; Aarstad HJ; Beisland C
Scand J Urol; 2015; 49(5):388-94. PubMed ID: 25773545
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
[TBL] [Abstract][Full Text] [Related]
4. Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma.
Fujita N; Okegawa T; Terado Y; Tambo M; Higashihara E; Nutahara K
BMC Res Notes; 2014 Jun; 7():369. PubMed ID: 24938498
[TBL] [Abstract][Full Text] [Related]
5. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
6. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
Fujita N; Okegawa T; Tambo M; Shishido T; Nutahara K; Higashihara E
Nihon Hinyokika Gakkai Zasshi; 2013 Jan; 104(1):1-5. PubMed ID: 23457926
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
Klatte T; Böhm M; Nelius T; Filleur S; Reiher F; Allhoff EP
BJU Int; 2007 Jul; 100(1):209-14. PubMed ID: 17428240
[TBL] [Abstract][Full Text] [Related]
8. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
[TBL] [Abstract][Full Text] [Related]
9. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
11. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.
Minardi D; Lucarini G; Mazzucchelli R; Milanese G; Natali D; Galosi AB; Montironi R; Biagini G; Muzzonigro G
J Urol; 2005 Oct; 174(4 Pt 1):1208-12. PubMed ID: 16145371
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
16. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.
Ljungberg B; Jacobsen J; Häggström-Rudolfssson S; Rasmuson T; Lindh G; Grankvist K
Urol Res; 2003 Oct; 31(5):335-40. PubMed ID: 14574539
[TBL] [Abstract][Full Text] [Related]
17. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
[TBL] [Abstract][Full Text] [Related]
18. High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer.
Omae K; Kondo T; Tanabe K
Urol Oncol; 2015 Feb; 33(2):67.e9-13. PubMed ID: 25130069
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma.
Ohno Y; Nakashima J; Nakagami Y; Gondo T; Ohori M; Hatano T; Tachibana M
Urology; 2014 Jan; 83(1):154-8. PubMed ID: 24149106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
